PURPOSE: Prostate-specific membrane antigen (PSMA) PET/CT is recognized as the most accurate imaging modality for staging of patients with intermediate and high-risk prostate cancer (PCa). This evidence concerns the gene FOLH1 and posterior cortical atrophy.